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to Improve Thymopoiesis after Autologous CD341 Cell
Transplantation in Rhesus Macaques
Evert-Jan Wils, Fatima S. F. Aerts-Kaya, Elwin J. C. Rombouts, Irene van Mourik,
Anita Rijken-Schelen, Trudi P. Visser, Eric Braakman, Gerard Wagemaker, Jan J. Cornelissen1Deficient thymopoiesis and retarded recovery of naive CD4 T cells are important determinants of insuffi-
cient immune-competence following hematopoietic stem cell transplantation (HSCT). Although keratino-
cyte growth factor (KGF) may protect the thymic epithelium, stem cell factor (SCF) is involved in early
thymopoiesis. We evaluated whether KGF alone or combined with SCF would affect thymopoiesis and
hematologic recovery following myeloablative autologous HSCT into rhesus macaques. Purpose-bred adult
rhesus macaques received 106 autologous CD341-selected mononuclear bone marrow cells (BMC)/kg after
9 Gy myeloablative conditioning. Animals were treated with phosphate-buffered saline (PBS) (n 5 2), KGF
alone (n 5 2), or KGF combined with SCF (n 5 2). KGF-treated animals showed accelerated hematologic
recovery, improved thymopoiesis, and enhanced naive T-cell recovery following transplantation. Improved
T cell recovery was not associated with protection against cytomegalovirus reactivation nor with improved
antibody response to tetanus toxoid vaccination. Animals treated with KGF and SCF experienced severe
adverse events that precluded evaluation of thymopoiesis and T cell recovery. Collectively, our data confirm
that KGF may enhance thymopoiesis.
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Protracted recovery of naive CD41 T cells in
recipients of allogeneic hematopoietic stem cell
transplantation may result in a prolonged susceptibility
to life-threatening opportunistic infections [1-3].
Reconstitution of naive CD41 T cells depends on the
differentiation of stem cell-derived lymphoid progeni-
tor cells into mature, naive CD41T cells in the thymus
(ie, thymopoiesis). Recovery of thymopoiesis has been
shown to be pivotal for the generation of a new diverse
T cell receptor repertoire and long-term immunity
[4-6]. High-dose chemo- and radiotherapy, aging and
graft-versus-host disease (GVHD)may adversely affect
both the thymic stromal compartment and developingDepartment of Hematology, Erasmus Medical Center,
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ery following allogeneic hematopoietic stem cell trans-
plantation (HSCT) [7-9]. Strategies to protect the
thymic stroma or to stimulate thymocyte development
may improve the recovery of naive T cells and restore
the repertoire to combat a variety of infectious
microorganisms [10-12]. Keratinocyte growth factor
(KGF) is a growth factor that protects thymic stroma,
whereas stem cell factor (SCF) stimulates outgrowth
of T cell progenitors.
KGF was initially discovered as a stimulator of epi-
thelial cell growth and is produced by cells of mesenchy-
mal origin. Its receptor is expressed by epithelial cells
including thymic epithelial cells [13,14]. Exogenous
KGF experimentally enhances thymopoiesis in normal
mice, reverses age-associated thymic involution, and
protects thymic epithelial cells against damage caused
by irradiation, chemotherapy, and GVHD [15-18].
Thymic regeneration and T-cell reconstitution were
enhanced in mice and nonhuman primates treated with
KGF before allogeneic or autologousHSCT [14,17,19].
SCF is a cytokine produced by stromal cells includ-
ing thymic stroma and c-kit; the SCF receptor is
expressed by the earliest thymocytes [20-23]. SCF is
important for proliferation and differentiation of
early thymic T cell progenitors in vitro and in vivo.55
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differentiation [24,25], and SCF2/2 thymi poorly
support early thymocyte expansion [26]. In addition,
differentiation of early thymic progenitors into the
T cell lineage is dependent on c-kit signaling and
Notch- and IL-7-induced proliferation require c-kit
signaling in vitro [27]. Administration of SCF in
mice accelerated leukocyte recovery following
radiation-induced myeloablation [28] but not follow-
ing 5-fluorouracil (5-FU) treatment [29] ormyeloabla-
tive HSCT [30]. Recently, we showed that SCF
administration improved thymopoiesis in a humanized
mice model [31]. In the present study, we evaluated the
effect of KGF alone or combined with SCF on T cell
reconstitution and thymopoiesis following myeloabla-
tive autologous HSCT into rhesus macaques.MATERIALS AND METHODS
Animals
Purpose-bred male rhesus monkeys (Macaca
mulatta), weighing 2.9-3.8 kg and age 2.5-3.7 years,
were used. Monkeys were housed in groups of 4 to 6
in stainless steel cages in rooms equipped with a reverse
filtered air barrier, normal daylight rhythm, and condi-
tioned to 20C with a relative humidity of 70%. Ani-
mals were fed ad libitum with commercial primate
chow and fresh fruits, and received acidified drinking
water. All animals were free of intestinal parasites,
and seronegative for herpes B, simian T-lymphotropic
viruses, and simian immunodeficiency virus. Housing,
experiments, and all other conditions were approved
by an ethical committee in conformity with legal reg-
ulations in the Netherlands. Studies with rhesus mon-
keys were done sequentially using highly codified
methods, including radiation and placebo controls at
regular intervals. For the present study, assignment
to the study groups was random.Collection of CD341 Hematopoietic Progenitor
Cells
Bone marrow (BM) was aspirated and low-density
cells isolated as previously described and red blood cells
reinfused immediately after cell separation [32,33].
CD341 cells were isolated by immunomagnetic
separation using an IgG2a antibody against CD34
(mAb 561 kindly provided by T. Egeland, University
of Oslo, Oslo, Norway), which was noncovalently
linked to rat-antimouse IgG2a beads (Dynal, Oslo,
Norway) [34]. CD341 cells devoid of the anti-CD34
antibody were recovered using a polyclonal antibody
against the Fab part of the anti-CD34 antibody
(Detachabead, Dynal). CD34-selected cells (106/kg)
were reinfused into the monkeys within 24 hours after
radiation.Total Body Irradiation (TBI) and Supportive
Care
Rhesus monkeys were irradiated with a single dose
of 9GyTBIdelivered by a 6-MV linear accelerator (Sie-
mens [SiemensHealthcare,Erlangen,GE]) as described
[33]. Two weeks before TBI, the monkeys were placed
in a laminar flow cabinet, the gastrointestinal tract was
selectively decontaminated, and iron ws supplemented
as previously described [32,33]. Supportive care after
irradiation by infection prevention, transfusions, and
maintenance of a hydration state were done as
previously described [32,33]. Platelet transfusions had
a mean volume of 12.8 6 3.4 mL and contained 7.0 6
3.0  109/L platelets. Whole-blood transfusions con-
sisted of 38.1 6 10.8 mL, containing 0.17 6 0.05 
1012/L erythrocytes and 10.06 3.1  109/L platelets.
Cytokine Administration
Recombinant human KGF (palifermin, Kepiv-
ance) and recombinant human stem cell factor
(SCF) were kindly provided by Amgen (Thousand
Oaks, CA). One group of animals (n 5 2) received
KGFat a dose of 200mg/kg bodyweight by intravenous
bolus at days 23, 22, 21, 0, 11, and 12. A second
group of animals (n 5 2) received both KGF and
SCF. SCF was administered at a dose of 200 mg/kg
body weight by subcutaneous injection daily from day
5 until day 45 posttransplantation andKGF as outlined
above [35,36]. A third groupof animals (n5 2)was used
as control group and received phosphate-buffered
saline (PBS) injections (Figure 1).
Collection of Peripheral Blood and Tissue
Samples
Complete blood cell counts were measured daily
using the ABC-vet animal blood counter (Scil, ABX
diagnostics, Montpellier, France). Peripheral blood
and BM samples for flow cytometry and molecular
analysis were drawn once weekly. Animals were eutha-
nized between day 190 and 212 following transplanta-
tion, and lymphoid tissues were collected and either
processed into a single-cell suspension or fixed in
10% formalin and paraffin-embedded for light micro-
scopic analysis. Thymic architecture was graded using
a previously described grading system [19].
Flow Cytometric Analysis
Atweekly intervals, absolute numbers of peripheral
blood leukocyte subsets were determined by single
platform flow cytometry as described previously for
murine experiments [37]. mAbs against rhesus
macaque epitopes used for flow cytometric analysis
were anti-CD45 (D058-1283), anti-CD3 (SP34-2),
anti-CD4 (L200), anti-CD8 (SK1/2ST8.5H7), anti-
CD20 (L27), anti-CD16/56 (3G8/MY31), anti-CD14
(M5E2), anti-CD28 (CD28.2/L293), anti-CD95 (Dx2),
Figure 1. Experimental design. Animals were started on selective decontamination of the gut (SDD) 12 days before HSCT. On day 26, autologous
BMC were harvested by bone marrow puncture. After TBI, animals underwent HSCT. Three treatment groups were compared: 1 control group
receiving PBS (n 5 2), 1 group receiving KGF from day 23 until day 2, and 1 group receiving KGF combined with SCF (day 5 until day 45). Complete
blood counts (CBC) were monitored daily until day 45 and weekly thereafter. Blood flowcytometry, sjTREC analysis, and rhCMV viral load was per-
formed weekly. BM was harvested weekly from week 0 until week 6 and week 4 weekly thereafter. TT vaccination was administered at day 50 and
day 78, TTresponse was monitored weekly from day 45 until day 99. Animals were euthanized and underwent necropsy to collect all lymphoid tissue
at the end of the study.
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Pharmingen, San Jose, CA). CD41 or CD81 naive
T cells were identified as CD31CD95lowCD28int,
effector memory CD41, or CD81 T cells as CD31
CD95high CD282/low and central memory CD41 or
CD81 T cells as CD31 CD95high CD28high as de-
scribed previously [38]. For intracellular analysis of
Foxp3 expression, cellswere first stained for the cell sur-
face markers CD4 and CD8 before incubation in 4
fixation/permeabilization solution (BD Biosciences,
San Jose, CA) and then stained with Foxp3 (PCH101).
To obtain a single-cell suspension thymus, spleen and
lymphnodes (LN)weremincedwith scissors and passed
through anylonmesh.CD451 thymocytesweredivided
into subsets based on CD3, CD4, and CD8 expression
into: triple negative (CD32CD42CD82), intermediate
single positive (CD32CD41CD82), double positive
(DP; CD41CD81), CD4 single positive (CD4SP;
CD31CD41CD82), andCD8SP(CD31CD42CD81).Real-Time Quantitative PCR (RQ-PCR)
Signal-Joint T Cell receptor excision circles
(sjTREC)
DNA was purified from peripheral blood at serial
time points after transplantation and from organ/
thymic cell suspensions at necroscopy using the
QIAamp DNA minikit (QIAGEN, Chatsworth, CA)
according to themanufacturer’s instructions. sjTRECs
were detected using aRQ-PCR as previously described
[39] for murine sjTREC with 50-nuclease-based
RQ-PCR assay using the ABI Prism 7700 sequencedetector (Applied Biosystems, Bedford, MA) and mod-
ified for rhesusmonkeys. Primers and probes for rhesus
monkey sjTRECwere: forwardprimer: 50-ACATCCC
TTTCAACCATGCT-30, reverse primer: 50-GCCA
GCTGCAGGGTTTAGG-30, and probe: FAM-50-
ACGCCTCTGGTTTTTGTAAAGGTGCTCAC
T-30-TAMRA [40]; internal control GAPDH: forward
primer: 50-TGACCTGCCGTCTGGAAAA-30, re-
verse primer: 50-CTCCGACGCCTGCTTCA-30,
and probe: FAM-50-CCTGCCAAGTACGATGA-
CATCAAGAAGGTG-30-TAMRA. In peripheral
blood, sjTREC frequency (sjTREC/105 CD31
T cells) and sjTREC content (sjTREC/mL blood)
were determined at weekly intervals. At autopsy,
thymic, splenic, and LN sjTREC frequencies were
determined.
Rhesus Macaque Cytomegalovirus (rhCMV)
DNA was isolated from plasma samples at serial
time points after transplantation and analyzed using
a modified version of a previously described rhCMV-
specific RQ-PCR [41]. Briefly, plasma viral DNA
was isolated using the total nucleic acid kit on aMagna
Pure LC robot (Roche Applied Science, Indianapolis,
IN). Primers and probes for the detection of rhCMV
were based on a 108-bp amplicon of the exon-1 region
of the immediate-early gene of rhCMV (ATCC-VR-
677; GenBank Accession No. M93360 [42], forward
primer 50-GTTTAGGGAACCGCCATTCTG-30,
reverse primer 50-GTATCCGCGTTCCAATGCA-30,
and probe FAM-50-TCCAGCCTCCATAGCCGGG
AAGG-30-TAMRA). Quantification was based on
Table 1. Days to Hematologic and CD34+ BMC Recovery
UAN Treatment PB:
Plt RBC (1012/L) Leukocytes ANC ALC
BM:
CD34+
Nadir >50 Nadir >4.0 Nadir >1.0 >4.0 >0.5 >0.5 >2.0 >0.1 >1.0
5243 PBS 10 (22) 33 16 (2.4) 50 8 (0.3) 22 37 25 31 38 71 nr
8077 PBS 14 (20) 33 29 (2.9) 57 12 (0.2) 23 44 23 32 44 127 nr
7029 KGF 9 (32) 24 29 (3.8) 34 9 (0.3) 20 30 20 21 30 22 71
5051 KGF 12 (28) 28 32 (3.5) 38 8 (0.2) 16 35 23 15 27 29 150
5277 KGF + SCF* 18 (26) 34 57 (3.5) 78 9 (0.3) 24 37 25 25 39 36 nr
6027 KGF + SCF† 13 (41) 24 32 (4.3) nr 9 (0.2) 21 25 21 21 nr 22 nr
PB indicates peripheral blood; BM, bone marrow; Plt, platelet; RBC; red blood cell; ANC, absolute neutrophil count; ALC, absolute lymphocyte count;
CD34+, absolute CD34+ bone marrow cell (109/liter BM); nr, not reached.
Days to nadir (number of cells  109/L) or to recovery above threshold (>).
Died at * day 150, † day 43.
58 Biol Blood Marrow Transplant 18:55-65, 2012E.-J. Wils et al.an external standard curve using rhCMV, which was
treated exactly like the material of interest. The
rhCMV DNA concentration in the samples was cal-
culated using the data from the standard curve, as
described previously [43].
Analysis of Humoral Response against Tetanus
Toxoid
Animals were vaccinated with 40 IE tetanus toxoid
(Netherlands Vaccine Institute) at days 50 and 78 after
HSCT.Antibodies against tetanus toxoidweremeasured
before the start of the experiment and at time points
before and after vaccination using a sensitive enzyme-
linked immunosorbent assay with a detection limit of
10 pg/mL and quantified as described before [44].
Computed Tomography (CT) Scan
CT evaluation of liver, thymus, and spleen volume
before (day 14) and following treatment (day 45 and
before termination of experiment) were determined
as described by Storek et al. [45]. On analysis, the
area of the thymus was determined on each slice
(mm2) using intravenous contrast images, and the
area was multiplied by the slice thickness to get the
volume at that slice level (mm3). Thymic volume was
calculated as the sum of the volumes at each slice level.
Splenic and liver volumes were determined analo-
gously. In addition, thymic density was measured as
outlined previously [46].RESULTS
Animals received 106 CD341-selected mononu-
clear bone marrow cells (BMC)/kg body weight fol-
lowing a single dose of 9 TBI, and were treated and
monitored as outlined in the Materials and Methods
section (Figure 1). Two animals receiving PBS and
2 animals receiving KGF alone completed the experi-
ment without any significant adverse events. The 2 an-
imals receiving KGF and SCF did not complete the
experiment. One animal (UAN 6027) died at day 45
following transplantation, which was preceded by diar-rhea, bad drinking, severe weight loss (Supplemental
Figure S1), and development of maculopapular skin
lesions and petechiae. Autopsy revealed a small bowel
hemorrhage and diffuse erythematous maculopapular
skin lesions, possibly caused by a generalized simian
varicella virus infection. The second animal (UAN
5277) was sacrificed at day 150 following transplanta-
tion because of respiratory failure unresponsive to
steroids. Of note, animal UAN 5277 was treated with
dexamethasone from day 106 until its death at day
150 posttransplantation. rhCMV was reactivated dur-
ing this entire treatment period, coinciding with
CD41 T-cell and B-cell lymphopenia (data not
shown). Autopsy showed severe radiation-induced in-
terstitial pulmonary fibrosis. Hematologic recovery
in KGF/SCF-treated animals appeared comparable
to the KGF-treated animals as outlined in detail in
the next paragraph.
Animalsweremonitored for loss and subsequent re-
covery of body weight. Animals receiving KGF alone
showed less loss of body weight and recovered more
rapidly compared with PBS-treated control animals.
The 2 controls both lost a maximum of 10% body
weight compared with 4% and 7% in the 2 KGF-
animals and 6% and more than 10% in the animals
treated with KGF and SCF. The body weight of both
PBS-treated animals recovered to pretransplantation
values as of day 71, compared with days 19 and 46 for
the 2 KGF-treated animals and day 42 for the 1
KGF/SCF-treated animal (UAN 5277) (Supplemental
Figure S1).
Hematologic Recovery
Hematologic recovery appeared slow in PBS-
treated animals. In contrast, KGF-treated animals
showed a more rapid recovery of platelets, erythrocytes,
and leukocytes (Table 1). Platelets (.50 109/L) were
recovered by day 33 posttransplantation in both PBS-
treated animals, by day 24 and day 28 in KGF-animals,
and by day 34 and day 24 in animals receiving the
combination of KGF and SCF. In PBS-treated
animals, transfusion continued until days 32 and 35, in
KGF-treated animals until days 23 and 27, and in
Figure 2. Lymphoid cell recovery. Animals underwent HSCT at day 0 and 3 groups of animals were compared: PBS-treated control animals, KGF-
treated animals, and KGF combined with SCF-treated animals. (A) Shows B cell recovery in time following HSCT. B cells were defined as
CD451CD32CD201. (B) Shows NK cell recovery in time following HSCT. NK cells were defined as CD451CD32CD16/561. (C) Shows naive
CD41 T-cell recovery in time following HSCT. Naive CD41T cells were defined as CD31CD41CD95lowCD28int. (D) Shows Treg recovery in time
following HSCT. Tregs were defined as CD41CD251Foxp31. Shaded area represents a normal 25 to 75 percentile; lines represents the 50th percentile.
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rapid hematologic recovery in KGF-treated animals
may be explained by better engraftment at the BM level.
We quantified CD341 BMC in time following trans-
plantation. The number of CD341 BMC recovered to
pretransplantation values more rapidly in KGF- and
KGF/SCF-treated animals compared with PBS-
treated controls. CD341 BMC had recovered to more
than 108 CD341 cells/L BM at days 71 and 127 in
PBS control animals, at days 22 and 29 in KGF-
treated animals, and at days 22 and 36 in KGF/SCF-
treated animals (Table 1).
Lymphocyte Recovery
Lymphocyte recovery appeared more rapid in ani-
mals treated with either KGF or KGF and SCF com-
pared with PBS. Absolute lymphocyte count (.0.5 
109/L blood) count recovered by days 31 and 32 in
the 2 PBS-treated animals, by days 21 and 15 for the
2 KGF-treated animals, and by days 25 and 21 for
the 2 KGF/SCF-treated animals (Table 1). We next
analyzed the recovery of the various lymphocyte sub-
sets. Recipients of KGF tended toward a more rapid
and enhanced recovery of B cells (Figure 2A), whereas
NK cell recovery appeared comparable to PBS-treated
animals (Figure 2B). B cell numbers recovered to
median pretransplantation values by days 71 and 64
in PBS-treated animals, by days 43 and 50 in KGF-treated animals, and by day 43 in 1 KGF/SCF-
treated animal. In addition, KGF-treated animals
showed significantly higher B cell numbers in periph-
eral blood (Wilcoxon rank test P\ .05) and in spleen
and LN at the end of the experiment (Table 3).
Naive T Cell Recovery
Next we investigate the recovery of T cells and
their various subsets. The effect of KGF combined
with SCF on T cell recovery could not be assessed,
because the animals died while being lymphopenic.
Absolute numbers of CD31 T cells and T cell subsets
(CD41 and CD81, naive [Tnaive], central memory
[Tcm], effector memory [Tem], and CD4
1Foxp31 reg-
ulatory T cells [Treg]) were quantified in time, and
results are depicted in Figure 2 and Table 2. Total
CD31, CD41, and CD81 T cell recovery were com-
parable between PBS- and KGF-treated animals.
The recovery of naive CD41 (Figure 2C) and CD81
T cells in peripheral blood was not enhanced in pe-
ripheral blood. In contrast, the absolute number of
CD41Foxp31 Treg appeared higher as of day 140
posttransplantation onward in KGF-treated animals
compared with PBS-treated animals (Figure 2D).
T cell subsets were also evaluated in the spleen and
LN at the end of the experiment (Table 3). The fre-
quencies of CD41 and CD81T cells in LN and spleen
were higher in KGF-treated animals compared with
Table 2. Days to T Cell Recovery
UAN Treatment CD3+
CD4+ Treg CD8+
Total Naive CM EM >l >2 Total Naive CM EM
5243 PBS 50 141 nr 106 36 57 nr 43 nr 134 36
8077 PBS 50 nr nr 106 36 106 nr 50 nr nr 36
7029 KGF 43 141 148 85 36 99 141 36 127 162 43
5051 KGF 500 134 nr 36 15 64 106 50 nr 106 43
Naive: CD95lowCD28int. CM indicates central memory, CD95highCD28high; EM, effector memory, CD95highCD28high; Treg, regulatory T cells,
CD4+Foxp3+; nr, not reached.
Days to recovery above median pretransplantation value (n 5 7).
60 Biol Blood Marrow Transplant 18:55-65, 2012E.-J. Wils et al.PBS control animals. A larger difference was noted for
naive CD41 and CD81 T cells in LN. The frequency
of naive CD41 T cells measured 7% and 10% in PBS
animals and 30% and 17% in KGF-treated animals.
In addition, the frequency of Treg was higher in the
spleen and LN of KGF-treated animals.Thymopoiesis
Enhanced recovery of naive T cells was observed in
the LN and spleens of KGF-treated animals. To assess
whether improved recovery could be because of
improved thymopoiesis, we measured sjTREC1
T cells/mL blood before and weekly after transplanta-
tion in peripheral blood; measured thymic size and
density using CT scan in time; evaluated the presence
of sjTREC1 cells in thymus, spleen, and LN; and eval-
uated the thymus microscopically at the end of the
experiment.
Pretransplantation median sjTREC1 T cell con-
tentmeasured 2286 sjTREC1Tcells/mLblood (range:
519-13.597). Following autologous stem cell transplan-
tation, sjTREC1 T cells were undetectable up to 11
weeks after transplantation, but subsequently reap-
peared in all animals, as depicted in Figure 3. sjTREC1
Tcell recoverywas improved inKGF-treated animals as
of day 106 posttransplantation as compared with PBS-
treated animals. sjTREC1 T cell content never re-
covered to normal pretransplantation values (.25th
percentile) in PBS-treated animals, whereas sjTREC1
cell numbers had recovered within normal ranges
around days 85 and 134 in KGF-treated animals.
Serial CT scanning of the thymus (weeks22, 6, 28)
showed no significant differences in thymic size orTable 3. T Cell Subsets and B Cells in Spleen and Lymph Nodes
UAN Treatment
Spleen
Weight Size CD20+ CD3+
CD4+
Total Naive Treg
5243 PBS 6.7 10 34 20 8 1.9 0.33
8077 PBS 4.9 7 39 24 10 2.5 0.38
7029 KGF 7.4 10 65 27 12 3.7 0.84
5051 KGF 5.4 7 57 28 14 2.5 0.50
Naive: CD95low CD28int. CM indicates central memory, CD95highCD2high
CD4+Foxp3+; B cells, CD20+.
Weight in grams. Size in cm3 (CT scan). Subsets expressed as percentage withdensity between KGF- and PBS-treated animals (data
not shown). Thymi were microscopically evaluated
for the degree of atrophy. Thymic atrophy was compa-
rable for PBS- and KGF-treated animals. The thymus
of PBS-treated animals showed grade 1 and3 thymic at-
rophy, and KGF-treated animals showed grade 1 and
grade 2. Thymocyte subset distribution, as determined
by flowcytometry, was not different in PBS- or KGF-
treated animals (data not shown). Thymic sjTREC1
cell recovery appeared enhanced in KGF-treated
animals. sjTREC1 cells/105 thymocytes measured 86
and 158/105 thymocytes in the 2 PBS-treated animals
compared with 957 and 158/105 thymocytes in the 2
KGF-treated animals. In addition, sjTREC1T cell re-
covery in the spleen and LN of animals was measured.
Also, sjTREC frequency in the spleen andLNappeared
slightly enhanced in KGF-treated animals. sjTREC
frequencies measured 17 and 18 sjTREC1 T cells/
105 T cells versus 321 and 14 sjTREC1 T cells/105
T cells in LN of PBS- versus KGF-treated animals,
respectively.Functional T Cell Immunity
To evaluate whether improved T-cell reconstitu-
tion would result in superior functional immunity,
endogenous rhCMV reactivation was monitored
weekly by RQ-PCR (Figure 4). The 2 control animals
experienced 3 and 2 self-limiting episodes of rhCMV
reactivation. The 2 KGF-treated animals experienced
4 and 2 episodes, respectively. The maximum viral
load was 590 gEq/mL plasma in control animals and
1320 gEq/mL plasma in KGF-treated animals. Of
note, animal UAN 5277 (KGF and SCF) was treatedLymph Node
CD8+
CD20+ CD3+
CD4+ CD8+
Total Naive Total Naive Treg Total Naive
9 1.2 17 21 12 7.2 0.7 6 3.5
11 0.7 12 23 16 9.5 1.7 5 1.9
11 3.2 28 69 42 30 4.8 20 15
10 4.2 42 44 27 17 2.8 14 6.6
; EM, effector memory, CD95highCD28low; Treg, regulatory T cells,
in CD45+ cells.
Figure 3. Thymic output. Peripheral blood sjTREC1 T cells (sjTREC1 T cells/mL blood) in time following HSCT is shown on the left for 2 PBS-treated
control animals and on the right for the 2 animals treated with KGF. Shaded area represents normal 25 to 75 percentile; line represents the 50th per-
centile.
Biol Blood Marrow Transplant 18:55-65, 2012 61KGF and SCF to Improve Thymopoiesis after Autologous HSCTwith dexamethasone from day 106 until its death at day
150 posttransplantation. rhCMV was reactivated dur-
ing the entire treatment period, coinciding with
CD41T-cell andB-cell lymphopenia (data not shown).Figure 4. rhCMV reactivation. Rhesus macaque CMV viral load in time follow
the right for the 2 animals treated with KGF.Animals were also challenged with tetanus toxoid (TT)
at days 50 and 78. Anti-TT antibody levels were mea-
sured before and after immunization to determine the
T-cell–dependent antibody response. As depicted ining HSCT is shown on the left for 2 PBS-treated control animals and on
Figure 5. Tetanus toxoid response. Antitetanus toxoid antibody
responses were monitored by ELISA in animals following a primary
(day 50 post-HSCT) and a secondary vaccination (day 78). Shown are
antibody responses in time in PBS-treated control animals (UAN 5243
and 8077), in KGF-treated animals (UAN 7029 and 5051), and 1 animal
treated with KGF combined with SCF (UAN 5277).
62 Biol Blood Marrow Transplant 18:55-65, 2012E.-J. Wils et al.Figure 5, antibodies were absent before immunization.
All animals developed an antibody response from
3 weeks after primary vaccination. Antibody responses
were further increased in all animals following a boost
vaccination at day 78. The highest antibody levels mea-
sured 8.3  104 and 4.6  104 ng/mL in PBS-treated
animals versus 1.6  104 and 1.0  105 ng/mL in
KGF-treated animals. Peak antibody levels in 2
KGF-treated animals were observed at days 85 and
92. In contrast, antibody levels were still increasing in
both PBS-treated animals at day 99.DISCUSSION
Recapitulation of thymopoiesis is generally consid-
ered pivotal for full restoration of anti-infectious
immunity in the later (.3-6 months) posttransplanta-
tion time period [3,10,11]. Increasing age, GVHD,
and high-dose chemo- and/or radiotherapy all ad-
versely affect thymopoiesis and are associated with
a protracted immune reconstitution in stem cell trans-
plant recipients. Strategies to accelerate recovery of
thymopoiesis are expected to improve anti-infectious
immunity and outcome. One such strategy is the exog-
enous supply of growth factors that play an important
role in thymopoiesis. In the present study, rhesus ma-
caque recipients of autologous CD341-selected stem
cell grafts experienced a particularly slow recovery of
newly developed, naiveT cells. Improved thymopoiesis
was noted in recipients of KGF. However, improved
thymopoiesis was only modestly associated with
enhanced T cell recovery, which did not translate into
improved functional immunity. BM CD341 cells, B
cells, and hematologic recovery also tended to be
more rapid in KGF-treated animals. Although we also
set out to evaluate the combination of KGF and SCF,
severe adverse events and early death precluded amean-
ingful evaluation of KGF and SCF on thymopoiesis.
The 2 animals treated with the combination KGF
and SCF suffered ongoing rhCMV infection and respi-ratory failure, and a fatal varicella virus infection, re-
spectively. In addition, these infectious complications
were preceded by mast cell–related adverse effects,
including skin reactions and shivering. In previous
studies of SCF in primates, most side effects were
mast cell–related [47-51]. Of note, experimental
animals in our studies received 200 mg/kg SCF daily
from day 5 until day 45 posttransplantation. The
inflammatory response of the conditioning regimen
combined with the early start of relatively high-dose
SCF administration may have provoked the toxicity
observed, as a similar dosage scheme had not been
associated with severe adverse effects when started
late after transplantation [36]. Further preclinical stud-
ies are needed in order to develop a better tolerable
therapeutic protocol that may possibly be evaluated
clinically. Given the direct stimulatory capacity of
SCF alone on human thymopoiesis, as recently
demonstrated in a humanized mouse model [31], fur-
ther study of the combination of KGF and low-dose
SCF may still be warranted. Alternatively, continuous
rather than bolus dosing may be an appropriate
method to limit SCF toxicity without losing beneficial
effects on thymopoiesis [52].
Our data may suggest that KGF treatment resulted
in improved engraftment followingmyeloablative stem
cell transplantation (Table 1). An accelerated recovery
of platelets, erythrocytes, and leukocytes was noted in
KGF-treated animals. These data may differ from
recent studies, which did not show an effect of KGF
on hematologic recovery following stem cell transplan-
tation in both humans and nonhuman primates
[19,53,54]. Neutrophil recovery .0.5  109/L
occurred between days 20 to 25 in the present study,
whereas Seggewiss et al. [19] reported neutrophil
recovery between days 8 to 13 in a similar model. Pos-
sible explanations for the delayed hematologic recovery
observed in the present study may be a relatively low
numbers of CD341 BMC infused and, more likely,
the use of granulocyte colony stimulating factor until
neutrophil recovery in the Seggewiss study. An acceler-
ated overall hematologic recovery as observed in the
present study in animals receivingKGF versus controls
could possibly be explained by the infusion of different
subsets of CD341 progenitor cells, whereby KGF-
recipients could have received a higher number of
more primitive CD341Drdull hematopoietic progeni-
tor cells, possibly resulting in better overall recovery.
However, subsets of CD341 cells were not quantified
in the present study, and the number of experimental
animals per treatment group was rather limited. Apart
from the suggestion of better hematologic recovery,
thymopoiesis appeared improved in recipients of
KGF, as demonstrated by the steady increase in time
in sjTREC1 T cells in peripheral blood. Previous
murine studies have shown that KGF improves thymo-
poiesis following congenic and allogeneic HSCT
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in a model of autologous HSCT in rhesus macaques
and appeared to improve recovery of sjTREC1
T cell frequency and preserved thymic architecture
[19]. Our data are in line with those reported by Segge-
wiss et al. [19].Wemonitored sjTREC1Tcell content
(sjTREC1T cells/mL blood) on a weekly basis. As the
sjTREC1Tcell frequencymay be affected by prolifer-
ation of mature Tcells, evaluation of thymopoiesis by
sjTREC1 T cell content may be a preferred estimate
of posttransplantation thymopoiesis [58].
Improved sjTREC1 cell recovery in thymi and lym-
phoid organs of KGF animals further elaborated the
data obtained in peripheral blood. However, improved
thymopoiesis resulted only in a minor improvement of
naive T cell recovery, which was predominantly
observed in the LN and spleen. Functional T cell–
dependent immunity, asmeasured by protection against
endogenous rhCMV reactivation and the anti-TT anti-
body response, appeared not to be improved by KGF.
These results appear to contrast to the improvement
of antibody response against HIV envelope gp140 ob-
served inKGF-treatedanimals in the studybySeggewiss
et al. [19].However, the improvement theyobservedwas
modest, was only statistically significant when combin-
ing KGF-treated groups of animals, and functionality
was evaluated at a late time point following transplanta-
tion. In addition, differenceswith respect to transplanta-
tion protocol and vaccination scheme may additionally
explain the different observation in these 2 studies.
Our results compare well to a number of other preclin-
ical studies, showing no improvement or only minor
improvement of functional immune competence by
KGF [14,17,55-57]. Collectively, these studies and our
results suggest that KGF alone may be insufficient to
restore T cell–dependent immune competence after
myeloablative stem cell transplantation in humans.
The limited clinical experience so far seems in line
with that conclusion [53,59].
Alternative possibilities to obtain a more rapid and
pronounced effect on thymopoiesis may include the
combination of cytokines such as KGF and early acting
cytokines such as Flt3L, IL-7, and SCF. In the present
study, we planned to evaluate the effect of the combina-
tion of KGF with SCF on thymopoiesis. However,
severe adverse events before T cell recovery precluded
any conclusion with respect to a possible thymopoietic
effect. However, given the favorable direct effects
exerted by SCF on human thymopoiesis in our human-
ized mice model, further experimental studies are war-
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